🫁 #ESMO26 Krascendo 1 (ph III): divarasib beats soto/ada head-to-head in 2L+ KRAS G12C NSCLC
PFS 9.8 vs 5.7 mo (HR 0.58)
OS 17.7 vs 12.0 mo (HR 0.56)
ORR 58% vs 32%
Likely new 2L SoC. Caveats: control 91% sotorasib, immature OS, GI tox (diarrhea ~60% in ph I).